Patents by Inventor Matthew SPENDIFF

Matthew SPENDIFF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS
    Publication number: 20230331720
    Abstract: The present disclosure relates to compounds of Formula (I?): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 19, 2023
    Inventors: Bruce LEFKER, Gordon SAXTY, Karl GIBSON, Mark PICKWORTH, Matthew SPENDIFF, Miles Stuart CONGREVE, Paul HUMPHRIES
  • BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS
    Publication number: 20230271973
    Abstract: The present disclosure relates to compounds of Formula (I?): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin receptor activity and may be used in the treatment of disorders in which orexin receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.
    Type: Application
    Filed: September 3, 2021
    Publication date: August 31, 2023
    Inventors: Bruce LEFKER, Karl GIBSON, Matthew SPENDIFF, Paul HUMPHRIES, Sarah BUCKNELL, Wojciech ZAWODNY, Roderick Alan PORTER
  • Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 10112926
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 30, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Publication number: 20180243297
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 26, 2018
    Publication date: August 30, 2018
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 10004732
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 9862711
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: January 9, 2018
    Assignee: NOVARTIS AG
    Inventors: Benjamin Richard Bellenie, Ian Bruce, Andrew James Culshaw, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170042889
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170037032
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 9, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170029414
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 2, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Ian BRUCE, Andrew James CULSHAW, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON